Search Result

Results for "

terminus

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Linker (1) Amino Acid Derivatives (1) Amyloid-β (2) Apoptosis (1) Aryl Hydrocarbon Receptor (1) ATP Synthase (1) Bacterial (5) Bcl-2 Family (2) Biochemical Assay Reagents (30) Calcium Channel (1) Casein Kinase (1) CCR (1) Complement System (3) Cytochrome P450 (1) DNA/RNA Synthesis (2) Drug Derivative (3) Endogenous Metabolite (4) Endonuclease (1) Gap Junction Protein (2) GCGR (2) Guanylate Cyclase (1) Histone Methyltransferase (1) iGluR (5) Interleukin Related (1) Isotope-Labeled Compounds (1) Kallikrein (1) Liposome (23) MARCKS (1) Mitochondrial Metabolism (1) Na+/K+ ATPase (2) Neurokinin Receptor (2) Neuropeptide Y Receptor (3) Oxytocin Receptor (3) p97 (1) PD-1/PD-L1 (2) Phosphatase (2) PIN1 (1) PKC (1) Polo-like Kinase (PLK) (1) PSMA (1) RABV (1) Radionuclide-Drug Conjugates (RDCs) (1) Reference Standards (2) Ser/Thr Protease (3) STAT (1) Tau Protein (2) Telomerase (1) TGF-beta/Smad (1) Thrombin (1) Thyroid Hormone Receptor (1) TNF Receptor (1) Transmembrane Glycoprotein (1) TRP Channel (1) VEGFR (1)
By Research Areas:	Cancer (14) Cardiovascular Disease (6) Endocrinology (4) Infection (6) Inflammation/Immunology (18) Metabolic Disease (6) Neurological Disease (21)
Oligonucleotides:	Pegylated Lipids (23) Guanine Nucleotide (1) Nucleotide Analogs (1) Phospholipids (1)

126

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P2842

Aminopeptidase	Biochemical Assay Reagents	Others Cancer
Aminopeptidase catalyzes the cleavage of amino acids from the amino terminus of protein or peptide substrates .

HY-P3102

GLP-1(32-36)amide	GCGR	Metabolic Disease
GLP-1(32-36)amide, a pentapeptide, derived from the C terminus of the glucoregulatory hormone GLP-1. GLP-1(32-36)amide could inhibit weight gain and modulate whole body glucose metabolism in diabetic mice .

HY-18619

YL-109 2 Publications Verification	Aryl Hydrocarbon Receptor	Cancer
YL-109 is an antitumor agent that can induce carboxyl terminus of Hsp70-interacting protein (CHIP) expression through aryl hydrocarbon receptor (AhR) signaling. YL-109 has ability to inhibit breast cancer cell growth and invasiveness .

HY-P99963

Sudubrilimab HS636	PD-1/PD-L1	Cancer
Sudubrilimab (HS636) is an Ig G1-kappa monoclonal antibody against PDL1. Sudubrilimab is fused at the C terminus of the heavy chain to a TGF-β1 receptor Ⅱ ectodomain (TGFBR2-ECD), and which can sequester the PD-1/PD-L1 pathway and TGF-β bioactivity in the immunosuppressive tumor microenvironment .

HY-P1884

LL-37, acetylated,amidated	Bacterial	Infection
LL-37, acetylated, amidated is a cathelicidin peptide LL-37 acetylated on the N-terminus and amidated on the C-terminus. The single human cathelicidin peptide LL-37 has antimicrobial and anti-biofilm activity against multiple Gram-positive and Gram-negative human pathogens, and has wound-healing effects on the host .

HY-131800

3'-NH2-ATP	ATP Synthase	Metabolic Disease
3'-NH2-ATP, an ATP analogue, is a potent and competitive inhibitor of ATP, with a K_i of 2.3 μM. 3'-NH2-ATP can be used to synthesis of 3′-Amino-3′-deoxy transfer RNA by incorporation into the 3' terminus of tRNA-C-C .

HY-P3102A

GLP-1(32-36)amide TFA	GCGR	Metabolic Disease
GLP-1(32-36)amide TFA, a pentapeptide, derived from the C terminus of the glucoregulatory hormone GLP-1. GLP-1(32-36)amide TFA could inhibit weight gain and modulate whole body glucose metabolism in diabetic mice .

HY-168781

Arachidoyl glycine	Drug Derivative	Metabolic Disease
Arachidoyl glycine is composed of a 0:0 fatty acid with glycine attached to its carboxyl terminus .

HY-N15079

Arphamenine B	Bacterial	Infection
Arphamenine B is a Zn ²⁺-dependent exopeptidase that selectively removes arginine and/or lysine residues from the NH2-terminus of several peptide substrates. Arphamenine B is an inhibitor of aminopeptidase B that can be isolated from bacteria. Arphamenine B enhances the immune response and is used to characterize novel proteases .

HY-P1493

Fibrinopeptide B, human FPB,human	Thrombin	Inflammation/Immunology
Fibrinopeptide B, human is a 14-aa peptide, released from the amino-terminus of β-chains of fibrinogen by thrombin.

HY-136887

Arphamenine B hemisulfate	Bacterial	Infection
Arphamenine B hemisulfate is a Zn ²⁺-dependent exopeptidase that selectively removes arginine and/or lysine residues from the NH2-terminus of several peptide substrates. Arphamenine B hemisulfate is an inhibitor of aminopeptidase B that can be isolated from bacteria. Arphamenine B hemisulfate enhances the immune response and is used to characterize novel proteases .

HY-E70368

Collagenase G (Recombinant)	Biochemical Assay Reagents	Others
Collagenase G Recombinant is involved in the islet isolation process, and digests specific collagens from the N-terminus, especially Col-V .

HY-171573

3′-Azido-2′,3′-dideoxy-GTP AZddGTP	Telomerase	Others
3′-Azido-2′,3′-dideoxy-GTP (AZddGTP) is a selective telomerase inhibitor with a K_i value of 1.5 μM. 3′-Azido-2′,3′-dideoxy-GTP can be incorporated into the 3′-terminus of DNA by telomerase. 3′-Azido-2′,3′-dideoxy-GTP inhibits telomerase activity in HeLa cells in vitro .

HY-P1505

C3a (70-77) Complement 3a (70-77)	Complement System	Inflammation/Immunology
C3a (70-77) is an octapeptide corresponding to the COOH terminus of C3a, exhibits the specificity and 1 to 2% biologic activities of C3a.

HY-P2019

Levitide	Neuropeptide Y Receptor	Neurological Disease
Levitide is a neurohormone-like peptide, can be isolated from skin secretions of the South African frog Xenopus laevis. Levitide comes from preprolevitide, is 88 residues long and contains contains the levitide peptide at the C terminus (Glu-Gly-Met-Ile-Gly-Thr-Leu-Thr-Ser-Lys-Arg-Ile-Lys-Gln-NH2) and the putative signal sequence at the N terminus .

HY-P1735

Moth Cytochrome C (MCC) (88-103)	Cytochrome P450	Inflammation/Immunology
Moth Cytochrome C (MCC) (88-103), derived from the carboxyl terminus of moth cytochrome c, induces positive selection of TCR transgenic thymocytes .

HY-P10055

PSMA targeting peptide PSMA-1	PSMA	Cancer
PSMA-1 is a PSMA targeting peptide (GRFLTGGTGRLLRIS) and can be used for for targeted delivery of glucose-regulated protein (GRP)-silencing siRNAs in PCa cells. PSMA-1 is selected and polyarginine sequences R6 or R9 were added at the C terminus to generate the CTPs. FITC labeling of the peptide with an aminohexanoic acid (Ahx) linker at the N terminus produced FITC-PSMA-1，to track PSMA binding on PCa cells .

HY-16757

Trofinetide 1 Publications Verification NNZ-2566	iGluR	Neurological Disease
Trofinetide (NNZ-2566), a synthetic analogue of the endogenous N-terminus tripeptide, Glycine-Proline-Glutamate (GPE), has been shown to be neuroprotective in animal models of brain injury.

HY-P5954

PLTX-II	Calcium Channel	Others
PLTX-II is a calcium channel blocker. PLTX-II has a 44-residue peptide containing ten Cys residues and an O-palmitoylated threonine amide at the carboxy-terminus .

HY-P991676

Eflumenibep alfa	Kallikrein	Inflammation/Immunology
Eflumenibep alfa is a Kallikrein 5 inhibitor with anti-inflammatory activity. Eflumenibep alfa is a fusion protein that combines human SPINK2 with the human IgG1 Fc fragment at the C-terminus .

HY-P3891

Substance P (4-11)	Neurokinin Receptor	Neurological Disease
Substance P (4-11), the C-terminus fragment of Substance P (HY-P0201), is a Substance P agonist that shows highly selective for NK1 receptors .

HY-P991680

Elipunercept	TNF Receptor	Inflammation/Immunology
Elipunercept is a fusion protein that combines human TNFRSF1B extracellular domain fragment (1-235) fused at the C-terminus to a human IgG1 Fc fragment. Elipunercept is an immunomodulator .

HY-160550

DPM-1003	Phosphatase	Inflammation/Immunology
DPM-1003 is a PTP1B conformational inhibitor that targets the non-catalytic, disordered segment at the C-terminus of the PTP1B protein, showing improvement in lung inflammation in mice .

HY-P991678

Efpixileukin alfa	Interleukin Related	Inflammation/Immunology
Efpixileukin alfa is a fusion protein that combines human IL-2 variant fused at the C-terminus to human immunoglobulin G1 (IgG1) Fc fragment. Efpixileukin alfa is an immunomodulator .

HY-P5007

Copeptin (human)	Biochemical Assay Reagents	Cardiovascular Disease
Copeptin (human) is a diagnostic and prognostic biomarker for cardiovascular disease (CVD). Copeptin (human) is also the carboxyl terminus of the arginine vasopressin (AVP) precursor peptide. Copeptin (human) can be used in the study of cardiovascular disease .

HY-174365D

mPEG-NPC (MW 10000)	Biochemical Assay Reagents	Others
mPEG-NPC (MW 10000) is an important PEG derivative whose reactive groups can be used to modify proteins, peptides or any other compounds with available amino groups at lysine residues or N-terminus .

HY-P1505A

C3a (70-77) TFA 1 Publications Verification Complement 3a (70-77) TFA	Complement System	Inflammation/Immunology
C3a (70-77) TFA (Complement 3a (70-77) TFA) is an octapeptide corresponding to the COOH terminus of C3a, exhibits the specificity and 1 to 2% biologic activities of C3a .

HY-174365B

mPEG-NPC (MW 3400)	Biochemical Assay Reagents	Others
mPEG-NPC (MW 3400) is an important PEG derivative whose reactive groups can be used to modify proteins, peptides or any other compounds with available amino groups at lysine residues or N-terminus .

HY-174365H

mPEG-NPC (MW:20000)	Biochemical Assay Reagents	Others
mPEG-NPC (MW 20000) is an important PEG derivative whose reactive groups can be used to modify proteins, peptides or any other compounds with available amino groups at lysine residues or N-terminus .

HY-174365E

mPEG-NPC (MW 40000)	Biochemical Assay Reagents	Others
mPEG-NPC (MW 40000) is an important PEG derivative whose reactive groups can be used to modify proteins, peptides or any other compounds with available amino groups at lysine residues or N-terminus .

HY-174365

mPEG-NPC (MW 1000)	Biochemical Assay Reagents	Others
mPEG-NPC (MW 1000) is an important PEG derivative whose reactive groups can be used to modify proteins, peptides or any other compounds with available amino groups at lysine residues or N-terminus .

HY-174365C

mPEG-NPC (MW 5000)	Biochemical Assay Reagents	Others
mPEG-NPC (MW 5000) is an important PEG derivative whose reactive groups can be used to modify proteins, peptides or any other compounds with available amino groups at lysine residues or N-terminus .

HY-174365A

mPEG-NPC (MW 2000)	Biochemical Assay Reagents	Others
mPEG-NPC (MW 2000) is an important PEG derivative whose reactive groups can be used to modify proteins, peptides or any other compounds with available amino groups at lysine residues or N-terminus .

HY-157712

08:0 PI(4,5)P2 ammonium	Biochemical Assay Reagents	Others
08:0 PI(4,5)P2 ammonium is suitable for identifying its binding site at the transient receptor potential vanilloid 4 (TRPV 4 N) terminus .

HY-P3932

[Sar4] Substance P (4-11)	Neurokinin Receptor	Neurological Disease
[Sar4] Substance P (4-11) is an analog of Substance P (4-11). Substance P (4-11), the C-terminus fragment of Substance P (HY-P0201), is a Substance P agonist .

HY-107091

Aspartyl-alanyl-diketopiperazine DA-DKP	Endogenous Metabolite	Inflammation/Immunology
Aspartyl-alanyl-diketopiperazine (DA-DKP) is an immunomodulatory molecule generated by cleavage and cyclization from the N-terminus of human albumin and can modulate the inflammatory immune response through a molecular pathway implicated in T- lymphocyte anergy .

HY-P99185

Bapineuzumab	Amyloid-β	Neurological Disease
Bapineuzumab is an anti-β-amyloid protein (APP) monoclonal antibody. Bapineuzumab is a humanized IgG1 that recognizes the N terminus of Aβ cleared plaques from the brains. Bapineuzumab can be used for the research of Alzheimer’s disease (AD) .

HY-44370

Boc-Gly-Gly-Gly-Gly-Gly	ADC Linker	Cancer
(tert-Butoxycarbonyl)glycyl-glycyl-glycyl-glycyl-glycine is a protease cleavable ADC linker with a Boc group on the N terminus, and it is used for the development of antibody-drug conjugates (ADCs). The Boc group can be deprotected under mild acidic conditions to form the free amine.

HY-19738

NQTrp	Tau Protein	Neurological Disease
NQTrp, an aromatic naphthoquinone-tryptophan hybrid molecule, an inhibitor of the aggregation of the tau protein with generic anti-amyloidogenic effects. NQTrp inhibits the in vitro aggregation of hexapeptide ( ⁴¹GCWMLY ⁴⁶ within the N-terminus of γD-crystallin) as well as full-length γD-crystallin .

HY-140741

DSPE-PEG-OH, MW 2000 1 Publications Verification	Liposome	Cancer
DSPE-PEG-OH, MW 2000 is a hydroxyl-terminated PEGylated phospholipid. The hydrophobic tail allows for the encapsulation and aggregation of other hydrophobic drugs, and the hydroxyl terminus is suitable for further reactions. DSPE-PEG-OH, MW 2000 can be used to prepare liposomes or lipid nanoparticles .

HY-164166

Fmoc-Sar-Sar-Sar-OH	Biochemical Assay Reagents	Others
Fmoc-Sar-Sar-Sar-OH is a small molecule polypeptide composed of four sarcosine residues, in which the N-terminus of the peptide chain is protected by Fmoc. Fmoc-Sar-Sar-Sar-OH can be used for peptide synthesis or synthesis of drug-peptide ligand conjugates .

HY-W106311

Fmoc-Val-Ala-OH	Biochemical Assay Reagents	Others
Fmoc-Val-Ala-OH is a reagent consisting of a Val-Ala dipeptide with an Fmoc protecting group on its N-terminus. Carboxylic acids can be reactive with alcohols or amines, while the Fmoc protecting group can be removed with piperidine to allow for coupling with carboxylic acids to form amides.

HY-149872

DCA-RMR1	Biochemical Assay Reagents	Others
DCA-RMR1 is a cross-linker. DCA-RMR1 elicits facile bicyclization of native peptides via N-terminus Cys-Cys cross-linking. DCA-RMR1 derivatizes RMR1 with 1,3-dichloroacetone (DCA) .

HY-W015450

D-Ala-D-Ala	Endogenous Metabolite	Others
D-Ala-D-Ala is a bacterial endogenous metabolite. D-Ala-D-Ala constitutes the terminus of the peptide part of the peptidoglycan monomer unit and is involved in the transpeptidation reaction as the substrate. D-Ala-D-Ala is catalyzed by D-Alanine-D-Alanine ligase .

HY-P2844

Polynucleotide kinase	DNA/RNA Synthesis	Metabolic Disease
Polynucleotide Kinase is a DNA repair enzyme. Polynucleotide Kinase possesses both a 5’-kinase activity that catalyzes the transfer of phosphate from ATP to a 5’-hydroxyl (OH) terminus and also a 3’-phosphatase activity that converts 3’-phosphate termini to 3’-OH termini .

HY-157508

VCP Activator 1 1 Publications Verification	p97	Others
VCP Activator 1 is a VCP activator that dose-dependently stimulates VCP ATPase activity. VCP Activator 1 binds an allosteric pocket near the C-terminus. In addition, VCP Activator 1 binding site can also be occupied by a phenylalanine residue in the VCP C-terminal tail .

HY-P10909

Canvuparatide MBX 2109	Thyroid Hormone Receptor	Endocrinology
Canvuparatide (MBX 2109) is a prodrug for parathyroid hormone (PTH) peptide that releases the bioactive PTH[1-32] peptide agonist that retains a fatty acylated lysine (Lys33) at the C-terminus, thereby extending the halflife of Canvuparatide. Canvuparatide can be used for the symptoms of hypoparathyroidism such as hypocalcemia and hyperphosphatemia .

HY-E70566

Protease (Fab Cleaving)	Ser/Thr Protease	Others
Protease (Fab Cleaving) is a serine protease expressed recombinantly in E.coli with a 6×His tag at the C-terminus. Protease (Fab Cleaving) specifically digests human IgG1 at a single site above the hinge, generating intact Fab and Fc fragments within two hours without reducing conditions.

HY-34738

Boc-β-Ala-ol 3-(Boc-amino)-1-propanol	Amino Acid Derivatives	Others
Boc-β-Ala-ol (3-(Boc-amino)-1-propanol) is an alanine derivative with a Boc protecting group at the N-terminus, which can be used to synthesize bioactive peptide mimics, such as Nα-Benzoyl-α-azaornithine phenyl ester, which has trypsin inhibitory activity .

HY-N15973

DSPE PEG2k-OH ammonium	Biochemical Assay Reagents	Others
DSPE PEG2k-OH ammonium is a hydroxyl-terminated PEGylated phospholipid. The hydrophobic tail allows for the encapsulation and aggregation of other hydrophobic drugs, and the hydroxyl terminus is suitable for further reactions. DSPE PEG2k-OH ammonium can be used to prepare liposomes or lipid nanoparticles .

Cat. No.	Product Name	Type

HY-140741

DSPE-PEG-OH, MW 2000 1 Publications Verification	Drug Delivery
DSPE-PEG-OH, MW 2000 is a hydroxyl-terminated PEGylated phospholipid. The hydrophobic tail allows for the encapsulation and aggregation of other hydrophobic drugs, and the hydroxyl terminus is suitable for further reactions. DSPE-PEG-OH, MW 2000 can be used to prepare liposomes or lipid nanoparticles .

HY-174365D

mPEG-NPC (MW 10000)	Drug Delivery
mPEG-NPC (MW 10000) is an important PEG derivative whose reactive groups can be used to modify proteins, peptides or any other compounds with available amino groups at lysine residues or N-terminus .

HY-174365B

mPEG-NPC (MW 3400)	Drug Delivery
mPEG-NPC (MW 3400) is an important PEG derivative whose reactive groups can be used to modify proteins, peptides or any other compounds with available amino groups at lysine residues or N-terminus .

HY-174365H

mPEG-NPC (MW:20000)	Drug Delivery
mPEG-NPC (MW 20000) is an important PEG derivative whose reactive groups can be used to modify proteins, peptides or any other compounds with available amino groups at lysine residues or N-terminus .

HY-174365E

mPEG-NPC (MW 40000)	Drug Delivery
mPEG-NPC (MW 40000) is an important PEG derivative whose reactive groups can be used to modify proteins, peptides or any other compounds with available amino groups at lysine residues or N-terminus .

HY-174365

mPEG-NPC (MW 1000)	Drug Delivery
mPEG-NPC (MW 1000) is an important PEG derivative whose reactive groups can be used to modify proteins, peptides or any other compounds with available amino groups at lysine residues or N-terminus .

HY-174365C

mPEG-NPC (MW 5000)	Drug Delivery
mPEG-NPC (MW 5000) is an important PEG derivative whose reactive groups can be used to modify proteins, peptides or any other compounds with available amino groups at lysine residues or N-terminus .

HY-174365A

mPEG-NPC (MW 2000)	Drug Delivery
mPEG-NPC (MW 2000) is an important PEG derivative whose reactive groups can be used to modify proteins, peptides or any other compounds with available amino groups at lysine residues or N-terminus .

HY-157712

08:0 PI(4,5)P2 ammonium	Cell Assay Reagents
08:0 PI(4,5)P2 ammonium is suitable for identifying its binding site at the transient receptor potential vanilloid 4 (TRPV 4 N) terminus .

HY-W1048572C

N3-PEG-NH2 (MW 1000) Azide-PEG-Amine (MW 1000)	Drug Delivery
N3-PEG-NH2 (MW 1000) (Azide-PEG-Amine (MW 1000)) is a hetero-bifunctional PEG product with an azide and an amine group at the PEG terminus. N3-PEG-NH2 (MW 1000) is an important cross-linker with PEG chains. The azide can be used for molecular conjugation through chemical reactions, and the amine can react with carboxylic acid or NHS ester .

HY-W1048572H

N3-PEG-NH2 (MW 10000) Azide-PEG-Amine (MW 10000)	Drug Delivery
N3-PEG-NH2 (MW 10000) (Azide-PEG-Amine (MW 10000)) is a hetero-bifunctional PEG product with an azide and an amine group at the PEG terminus. N3-PEG-NH2 (MW 10000) is an important cross-linker with PEG chains. The azide can be used for molecular conjugation through chemical reactions, and the amine can react with carboxylic acid or NHS ester .

HY-W1048572E

N3-PEG-NH2 (MW 5000)	Drug Delivery
N3-PEG-NH2 (MW 5000) (Azide-PEG-Amine (MW 5000)) is a hetero-bifunctional PEG product with an azide and an amine group at the PEG terminus. N3-PEG-NH2 (MW 5000) is an important cross-linker with PEG chains. The azide can be used for molecular conjugation through chemical reactions, and the amine can react with carboxylic acid or NHS ester .

HY-W1048572I

N3-PEG-NH2 (MW 20000) Azide-PEG-Amine (MW 20000)	Drug Delivery
N3-PEG-NH2 (MW 20000) (Azide-PEG-Amine (MW 20000)) is a hetero-bifunctional PEG product with an azide and an amine group at the PEG terminus. N3-PEG-NH2 (MW 20000) is an important cross-linker with PEG chains. The azide can be used for molecular conjugation through chemical reactions, and the amine can react with carboxylic acid or NHS ester .

HY-W1048572A

N3-PEG-NH2 (MW 2000)	Drug Delivery
N3-PEG-NH2 (MW 2000) (Azide-PEG-Amine (MW 2000)) is a hetero-bifunctional PEG product with an azide and an amine group at the PEG terminus. N3-PEG-NH2 (MW 2000) is an important cross-linker with PEG chains. The azide can be used for molecular conjugation through chemical reactions, and the amine can react with carboxylic acid or NHS ester .

HY-W1048572D

N3-PEG-NH2 (MW 3400) Azide-PEG-Amine (MW 3400)	Drug Delivery
N3-PEG-NH2 (MW 3400) (Azide-PEG-Amine (MW 3400)) is a hetero-bifunctional PEG product with an azide and an amine group at the PEG terminus. N3-PEG-NH2 (MW 3400) is an important cross-linker with PEG chains. The azide can be used for molecular conjugation through chemical reactions, and the amine can react with carboxylic acid or NHS ester .

HY-W1048572J

N3-PEG-NH2 (MW 40000) Azide-PEG-Amine (MW 40000)	Drug Delivery
N3-PEG-NH2 (MW 40000) (Azide-PEG-Amine (MW 40000)) is a hetero-bifunctional PEG product with an azide and an amine group at the PEG terminus. N3-PEG-NH2 (MW 40000) is an important cross-linker with PEG chains. The azide can be used for molecular conjugation through chemical reactions, and the amine can react with carboxylic acid or NHS ester .

HY-144012B

DPPE-PEG550

16:0 PEG550 PE; 1,2-Dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-550] ammonium

Drug Delivery

DPPE-PEG550 is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-144013H

18:0 mPEG5000 PE ammonium

DSPE-mPEG5000 ammonium; 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-5000] ammonium

Drug Delivery

18:0 mPEG5000 PE (ammonium) is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymeric nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-144013B

18:0 mPEG550 PE ammonium

DSPE-mPEG550 ammonium; 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-550] ammonium

Drug Delivery

18:0 mPEG550 PE (ammonium) is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymeric nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-144012C

DPPE-PEG750

16:0 PEG750 PE; 1,2-Dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-750] ammonium

Drug Delivery

DPPE-PEG750 is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-144012E

DPPE-PEG3000

16:0 PEG3000 PE; 1,2-Dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-3000] ammonium

Drug Delivery

DPPE-PEG3000 is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-144013A

18:0 mPEG350 PE ammonium

DSPE-mPEG350 ammonium; 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-350] ammonium

Drug Delivery

18:0 mPEG350 PE (ammonium) is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-144013D

18:0 mPEG1000 PE ammonium

DSPE-mPEG1000 ammonium; 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-1000] ammonium

Drug Delivery

18:0 mPEG1000 PE (ammonium) is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymeric nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-144012D

DPPE-PEG1000

16:0 PEG1000 PE; 1,2-Dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-1000] ammonium

Drug Delivery

DPPE-PEG1000 is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-144012H

DPPE-PEG5000

16:0 PEG5000 PE; 1,2-Dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-5000] ammonium

Drug Delivery

DPPE-PEG5000 is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-144013E

18:0 mPEG3000 PE ammonium

DSPE-mPEG3000 ammonium; 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-3000] ammonium

Drug Delivery

18:0 mPEG3000 PE (ammonium) is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymeric nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-144013C

18:0 mPEG750 PE ammonium

DSPE-mPEG750 ammonium; 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-750] ammonium

Drug Delivery

18:0 mPEG750 PE (ammonium) is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymeric nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-155926

DMPE-PEG750 ammonium

14:0 PEG750 PE ammonium; 1,2-Dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-750] ammonium

Drug Delivery

DMPE-PEG750 ammonium (14:0 PEG750 PE ammonium) is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymeric nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-155931

18:1 PEG550 PE ammonium

DOPE-PEG550 ammonium; 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-550] ammonium

Drug Delivery

18:1 PEG550 PE ammonium (DOPE-PEG550 ammonium) is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-155924

DMPE-PEG350 ammonium

14:0 PEG350 PE ammonium; 1,2-Dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-350] ammonium

Drug Delivery

DMPE-PEG350 ammonium (14:0 PEG350 PE ammonium) is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-155927

DMPE-PEG1000 ammonium

14:0 PEG1000 PE ammonium; 1,2-Dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-1000] ammonium

Drug Delivery

DMPE-PEG1000 ammonium (14:0 PEG1000 PE ammonium) is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-155934

18:1 PEG5000 PE ammonium

DOPE-PEG5000 ammonium; 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-5000] ammonium

Drug Delivery

18:1 PEG5000 PE ammonium (DOPE-PEG5000 ammonium) is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-155933

18:1 PEG3000 PE ammonium

DOPE-PEG3000 ammonium; 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-3000] ammonium

Drug Delivery

18:1 PEG3000 PE ammonium (DOPE-PEG3000 ammonium) is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-155932

18:1 PEG1000 PE ammonium

DOPE-PEG1000 ammonium; 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-1000] ammonium

Drug Delivery

18:1 PEG1000 PE ammonium (DOPE-PEG1000 ammonium) is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-155925

DMPE-PEG550 ammonium

14:0 PEG550 PE ammonium; 1,2-Dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-550] ammonium

Drug Delivery

DMPE-PEG550 ammonium (14:0 PEG550 PE ammonium) is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymeric nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-155930

18:1 PEG350 PE ammonium

DOPE-PEG350 ammonium; 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-350] ammonium

Drug Delivery

18:1 PEG350 PE ammonium (DOPE-PEG350 ammonium) is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-155929

DMPE-PEG5000 ammonium

14:0 PEG5000 PE ammonium; 1,2-Dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-5000] ammonium

Drug Delivery

DMPE-PEG5000 ammonium (14:0 PEG5000 PE ammonium) is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-155928

DMPE-PEG3000 ammonium

14:0 PEG3000 PE ammonium; 1,2-Dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-3000] ammonium

Drug Delivery

DMPE-PEG3000 ammonium (14:0 PEG3000 PE ammonium) is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-N7833

Heneicosapentaenoic acid

Drug Delivery

Heneicosapentaenoic Acid (HPA) is a 21:5 omega-3 fatty acid found in trace amounts in the green alga B. pennata and in fish oils. Its chemical composition is similar to eicosapentaenoic acid (EPA), except that a carbon is extended at the carboxy terminus, placing the first double bond at the δ6 position. HPA can be used to study the importance of double bond position in omega-3 fatty acids. It incorporates phospholipids and triacylglycerols in vivo with the same efficiency as EPA and docosahexaenoic acid, and exhibits a strong inhibitory effect on the synthesis of arachidonic acid from linoleic acid. HPA is a poor substrate for prostaglandin H synthase (PGHS) (cyclooxygenase) and 5-lipoxygenase, but retains the ability to rapidly inactivate PGHS.

Cat. No.	Product Name	Target	Research Area

HY-P3102

GLP-1(32-36)amide	GCGR	Metabolic Disease
GLP-1(32-36)amide, a pentapeptide, derived from the C terminus of the glucoregulatory hormone GLP-1. GLP-1(32-36)amide could inhibit weight gain and modulate whole body glucose metabolism in diabetic mice .

HY-P1732

Transportan	Peptides	Cancer
Transportan is a 27 amino acid-long peptide containing 12 functional amino acids from the amino terminus of the neuropeptide galanin and mastoparan in the carboxyl terminus, connected via a lysine. Transportan belongs to cell-penetrating peptides (CPPs) .

HY-P1884

LL-37, acetylated,amidated	Bacterial	Infection
LL-37, acetylated, amidated is a cathelicidin peptide LL-37 acetylated on the N-terminus and amidated on the C-terminus. The single human cathelicidin peptide LL-37 has antimicrobial and anti-biofilm activity against multiple Gram-positive and Gram-negative human pathogens, and has wound-healing effects on the host .

HY-P10531

ALFA-tag	Peptides	Others
ALFA-tag is a small and stable α-helical structure composed of 15 amino acids. ALFA-tag is highly hydrophilic and can be placed at the N-terminus, C-terminus, or between two independently folded domains of the target protein without affecting the function of the protein. ALFA-tag is widely used as an epitope tag and is used for the detection and manipulation of proteins in living cells .

HY-P3102A

GLP-1(32-36)amide TFA	GCGR	Metabolic Disease
GLP-1(32-36)amide TFA, a pentapeptide, derived from the C terminus of the glucoregulatory hormone GLP-1. GLP-1(32-36)amide TFA could inhibit weight gain and modulate whole body glucose metabolism in diabetic mice .

HY-P4074

Anti-BetaGamma	Peptides	Others
Anti-BetaGamma, a peptide, is MPS-Phosducin-like protein C terminus .

HY-P1493

Fibrinopeptide B, human FPB,human	Thrombin	Inflammation/Immunology
Fibrinopeptide B, human is a 14-aa peptide, released from the amino-terminus of β-chains of fibrinogen by thrombin.

HY-P1505

C3a (70-77) Complement 3a (70-77)	Complement System	Inflammation/Immunology
C3a (70-77) is an octapeptide corresponding to the COOH terminus of C3a, exhibits the specificity and 1 to 2% biologic activities of C3a.

HY-P2019

Levitide	Neuropeptide Y Receptor	Neurological Disease
Levitide is a neurohormone-like peptide, can be isolated from skin secretions of the South African frog Xenopus laevis. Levitide comes from preprolevitide, is 88 residues long and contains contains the levitide peptide at the C terminus (Glu-Gly-Met-Ile-Gly-Thr-Leu-Thr-Ser-Lys-Arg-Ile-Lys-Gln-NH2) and the putative signal sequence at the N terminus .

HY-P1367

Pep1-TGL	Peptides	Neurological Disease
Pep1-TGL is a synthetic peptide containing the TGL motif from the C-terminus of the AMPA receptor GluA1 subunit .

HY-P11104

SsrA tag	Peptides	Others
SsrA tag is an 11-aa peptide added to the C-terminus of proteins stalled during translation, targeting them for degradation by ClpXP and ClpAP .

HY-P1735

Moth Cytochrome C (MCC) (88-103)	Cytochrome P450	Inflammation/Immunology
Moth Cytochrome C (MCC) (88-103), derived from the carboxyl terminus of moth cytochrome c, induces positive selection of TCR transgenic thymocytes .

HY-P10055

PSMA targeting peptide PSMA-1	PSMA	Cancer
PSMA-1 is a PSMA targeting peptide (GRFLTGGTGRLLRIS) and can be used for for targeted delivery of glucose-regulated protein (GRP)-silencing siRNAs in PCa cells. PSMA-1 is selected and polyarginine sequences R6 or R9 were added at the C terminus to generate the CTPs. FITC labeling of the peptide with an aminohexanoic acid (Ahx) linker at the N terminus produced FITC-PSMA-1，to track PSMA binding on PCa cells .

HY-P2553

Histone H3 (116-136), C116-136	Peptides	Others
Histone H3 (116-136), C116-136 is a peptide spaning the C-terminus of histone H3, amino acids 116 to 136 .

HY-P1493A

Fibrinopeptide B, human TFA FPB,human TFA	Peptides	Inflammation/Immunology
Fibrinopeptide B, human TFA (FPB,human TFA), human is a 14-aa peptide, released from the amino-terminus of β-chains of fibrinogen by thrombin .

HY-16757

Trofinetide 1 Publications Verification NNZ-2566	iGluR	Neurological Disease
Trofinetide (NNZ-2566), a synthetic analogue of the endogenous N-terminus tripeptide, Glycine-Proline-Glutamate (GPE), has been shown to be neuroprotective in animal models of brain injury.

HY-P5954

PLTX-II	Calcium Channel	Others
PLTX-II is a calcium channel blocker. PLTX-II has a 44-residue peptide containing ten Cys residues and an O-palmitoylated threonine amide at the carboxy-terminus .

HY-P4807

Pheromone Biosynthesis Activating Neuropeptide (Helicoverpa assulta, Heliothis zea) Hez-PBAN	Peptides	Neurological Disease
Pheromone Biosynthesis Activating Neuropeptide (Helicoverpa assulta, Heliothis zea) (PBAN), a member of the PBAN/Pyrokinin neuropeptide family, characterized by a common amino acid sequence FXPRLamide motif in the C-terminus .

HY-P3891

Substance P (4-11)	Neurokinin Receptor	Neurological Disease
Substance P (4-11), the C-terminus fragment of Substance P (HY-P0201), is a Substance P agonist that shows highly selective for NK1 receptors .

HY-P5007

Copeptin (human)	Biochemical Assay Reagents	Cardiovascular Disease
Copeptin (human) is a diagnostic and prognostic biomarker for cardiovascular disease (CVD). Copeptin (human) is also the carboxyl terminus of the arginine vasopressin (AVP) precursor peptide. Copeptin (human) can be used in the study of cardiovascular disease .

HY-P1505A

C3a (70-77) TFA 1 Publications Verification Complement 3a (70-77) TFA	Complement System	Inflammation/Immunology
C3a (70-77) TFA (Complement 3a (70-77) TFA) is an octapeptide corresponding to the COOH terminus of C3a, exhibits the specificity and 1 to 2% biologic activities of C3a .

HY-P3932

[Sar4] Substance P (4-11)	Neurokinin Receptor	Neurological Disease
[Sar4] Substance P (4-11) is an analog of Substance P (4-11). Substance P (4-11), the C-terminus fragment of Substance P (HY-P0201), is a Substance P agonist .

HY-164166

Fmoc-Sar-Sar-Sar-OH	Biochemical Assay Reagents	Others
Fmoc-Sar-Sar-Sar-OH is a small molecule polypeptide composed of four sarcosine residues, in which the N-terminus of the peptide chain is protected by Fmoc. Fmoc-Sar-Sar-Sar-OH can be used for peptide synthesis or synthesis of drug-peptide ligand conjugates .

HY-W015450

D-Ala-D-Ala	Endogenous Metabolite	Others
D-Ala-D-Ala is a bacterial endogenous metabolite. D-Ala-D-Ala constitutes the terminus of the peptide part of the peptidoglycan monomer unit and is involved in the transpeptidation reaction as the substrate. D-Ala-D-Ala is catalyzed by D-Alanine-D-Alanine ligase .

HY-P3778

γ-Bag cell peptide	Peptides	Neurological Disease
γ-bag cell peptide is a peptide. γ-bag cell peptide is located near the N-terminus of the egg laying prohormone, the vesicle is released upon insulin stimulation. γ-bag cell peptide can be used for the research of the central and peripheral nervous systems .

HY-P10909

Canvuparatide MBX 2109	Thyroid Hormone Receptor	Endocrinology
Canvuparatide (MBX 2109) is a prodrug for parathyroid hormone (PTH) peptide that releases the bioactive PTH[1-32] peptide agonist that retains a fatty acylated lysine (Lys33) at the C-terminus, thereby extending the halflife of Canvuparatide. Canvuparatide can be used for the symptoms of hypoparathyroidism such as hypocalcemia and hyperphosphatemia .

HY-34738

Boc-β-Ala-ol 3-(Boc-amino)-1-propanol	Amino Acid Derivatives	Others
Boc-β-Ala-ol (3-(Boc-amino)-1-propanol) is an alanine derivative with a Boc protecting group at the N-terminus, which can be used to synthesize bioactive peptide mimics, such as Nα-Benzoyl-α-azaornithine phenyl ester, which has trypsin inhibitory activity .

HY-P1565

Transdermal Peptide Disulfide TD 1 Disulfide(peptide)	Na+/K+ ATPase	Inflammation/Immunology
Transdermal Peptide Disulfide (TD 1 Disulfide(peptide)) is a 11-amino acid peptide, binds toNa ⁺/K ⁺-ATPase beta-subunit (ATP1B1), and mainly interacts with the C-terminus of ATP1B1. Transdermal Peptide Disulfide can enhance the transdermal delivery of many macromolecules .

HY-P5439

Epsilon-V1-2, Cys-conjugated	PKC MARCKS	Others
Epsilon-V1-2, Cys-conjugated is a biological active peptide. (This peptide is the εPKC specific inhibitor. Its inhibitory activity is based on εPKC translocation and MARCKS phosphorylation. This peptide interferes with εPKC interaction with the anchoring protein εRACK. This peptide contains a cysteine residue added to the C-terminus for potential S-S bond formation with a carrier protein.Pyroglutamyl (pGlu) peptides may spontaneously form when either Glutamine (Q) or Glutamic acid (E) is located at the sequence N-terminus. The conversion of Q or E to pGlu is a natural occurrence and in general it is believed that the hydrophobic γ-lactam ring of pGlu may play a role in peptide stability against gastrointestinal proteases. Pyroglutamyl peptides are therefore considered a normal subset of such peptides and are included as part of the peptide purity during HPLC analysis.)

HY-P1565A

Transdermal Peptide Disulfide TFA TD 1 Disulfide(peptide) TFA	Na+/K+ ATPase	Others
Transdermal Peptide Disulfide TFA (TD 1 Disulfide(peptide) TFA) is a 11-amino acid peptide, binds to Na ⁺/K ⁺-ATPase beta-subunit (ATP1B1), and mainly interacts with the C-terminus of ATP1B1. Transdermal Peptide Disulfide TFA can enhance the transdermal delivery of many macromolecules .

HY-P10161

Ac-DMQD-pNA	Biochemical Assay Reagents	Others
Ac-DMQD-pNA is a peptide substrate. Both of the recombinant CgCaspase-1 (rCgCaspase-1) and the C-terminus of CgCaspase-1 (rCgCaspase-1-C) exhibits similar caspase activity towards proteolytic substrate Ac-DMQD-pNA and Ac-DEVD-pNA (HY-P1006) .

HY-176277S

Fibrinopeptide B, human-(Val-13C5,15N, Arg-13C6,15N4) TFA FPB,human-(Val-¹³C₅,¹⁵N, Arg-¹³C₆,¹⁵N₄) TFA	Isotope-Labeled Compounds	Inflammation/Immunology
Fibrinopeptide B, human-(Val- ¹³C₅, ¹⁵N, Arg- ¹³C₆, ¹⁵₄) TFA is the ¹³C- and ¹⁵N-labeled Fibrinopeptide B, human (HY-P1493). Fibrinopeptide B, human is a 14-aa peptide, released from the amino-terminus of β-chains of fibrinogen by thrombin .

HY-P1116

PBP10 1 Publications Verification	Bacterial	Infection Inflammation/Immunology
PBP10 is a cell permeable and selective gelsolin-derived peptide inhibitor of formyl peptide receptor 2 (FPR2) over FPR1 . PBP10 is a 10-AA peptide with rhodamine conjugated at its N terminus, exerts bactericidal activity against gram-positive and gram-negative bacteria and limits microbial-induced inflammatory effects .

HY-P1116A

PBP10 TFA 1 Publications Verification	Bacterial	Infection Inflammation/Immunology
PBP10 is a cell permeable and selective gelsolin-derived peptide inhibitor of formyl peptide receptor 2 (FPR2) over FPR1 . PBP10 is a 10-AA peptide with rhodamine conjugated at its N terminus, exerts bactericidal activity against gram-positive and gram-negative bacteria and limits microbial-induced inflammatory effects .

HY-P10247

Amyloid precursor C-terminal peptide	Mitochondrial Metabolism	Neurological Disease
Amyloid precursor C-terminal peptide is cleaved from the C-terminus of Amyloid Precursor Protein (APP). Amyloid precursor C-terminal peptide accumulation causes mitochondrial morphology alteration and basal mitophagy failure, which indicates that amyloid precursor protein C-terminal peptide may correspond to an etiological trigger of Alzheimer’s disease (AD) pathology .

HY-P3815

Casein Kinase 2 Substrate Peptide 2 Publications Verification	Casein Kinase	Others
Casein Kinase 2 Substrate Peptide is a common CK2 substrate peptide. Casein Kinase 2 Substrate Peptide is synthesized with its C-terminus conjugated to 5-[(2-aminoethyl)amino]naphthalene-1-sulfonic acid (EDANS). Casein Kinase 2 Substrate Peptide can be used for protein kinase CK2 activity determination .

HY-P3385

Rilunermin alfa SCB-313	Drug Derivative Apoptosis	Cancer
Rilunermin alfa (SCB-313) is a recombinant fusion protein composed of the human C-propeptide of alpha1(I) collagen (Trimer-Tag) to the C-terminus of the mature human tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL; Apo2L). Rilunermin alfa has potential pro-apoptotic and antineoplastic activities .

HY-P10356

T100-Mut	TRP Channel	Others
T100-Mut is a cell-permeable peptide whose N-terminus is conjugated with a myristoylated group to enable T100-Mut to penetrate and localize to the inner side of the plasma membrane, thus mimicking the topology of Tmem100-3Q. T100-Mut can alleviate TRPA1-mediated pain .

HY-17573A

Carbetocin acetate 1 Publications Verification	Oxytocin Receptor	Neurological Disease Endocrinology
Carbetocin acetate, an oxytocin (OT) analogue, is an oxytocin receptor agonist with a K_i of 7.1 nM. Carbetocin acetate has high affinity to chimeric N-terminus (E1) of the oxytocin receptor (K_i=1.17 μM). Carbetocin acetate has the potential for postpartum hemorrhage research. Carbetocin acetate can crosse the blood-brain barrier and produces antidepressant-like activity via activation of oxytocin receptors in the CNS .

HY-17573

Carbetocin 1 Publications Verification	Oxytocin Receptor	Neurological Disease Endocrinology
Carbetocin, an oxytocin (OT) analogue, is an oxytocin receptor agonist with a K_i of 7.1 nM. Carbetocin has high affinity to chimeric N-terminus (E1) of the oxytocin receptor (K_i=1.17 μM). Carbetocin has the potential for postpartum hemorrhage research. Carbetocin can crosse the blood-brain barrier and produces antidepressant-like activity via activation of oxytocin receptors in the CNS .

HY-P3971

H-Leu-Ser-Lys-Leu-OH	TGF-beta/Smad	Inflammation/Immunology
H-Leu-Ser-Lys-Leu-OH (LSYL) is a latency-associated peptide at the amino terminus of LAP, with inhibitory effect on TGF-β1 activation. H-Leu-Ser-Lys-Leu-OH, binding with KRFK (HY-P3970), can block the signal transduction of TGF-β1, and prevent the progression of hepatic damage and fibrosis .

HY-P4086

Chimeric Rabies Virus Glycoprotein Fragment (RVG-9R)	RABV	Infection
Chimeric Rabies Virus Glycoprotein Fragment (RVG-9R), a chimeric peptide consisting of 29 amino acids, is synthesized by adding nona-arginine motif to the carboxy terminus of RVG (rabies virus glycoprotein). Chimeric Rabies Virus Glycoprotein Fragment (RVG-9R) is positively charged and able to bind negatively charged nucleic acids via charge interaction .

HY-W015450R

D-Ala-D-Ala (Standard)	Reference Standards Endogenous Metabolite	Others
D-Ala-D-Ala (Standard) is the analytical standard of D-Ala-D-Ala. This product is intended for research and analytical applications. D-Ala-D-Ala is a bacterial endogenous metabolite. D-Ala-D-Ala constitutes the terminus of the peptide part of the peptidoglycan monomer unit and is involved in the transpeptidation reaction as the substrate. D-Ala-D-Ala is catalyzed by D-Alanine-D-Alanine ligase .

HY-P3624

Cenderitide	Guanylate Cyclase	Cardiovascular Disease
Cenderitide is a potent agonist of particulate guanylyl cyclase receptor (pGC). Cenderitide is a natriuretic peptide (NP) composed of C-type natriuretic peptide (CNP) fused to the C-terminus of Dendroaspis natriuretic peptide (DNP). Cenderitide activates both pGC-A and pGC-B, activates the second messenger cGMP, suppresses aldosterone, and preserves GFR without reducing blood pressure. Cenderitide can be used for heart failure research .

HY-P1195

PDZ1 Domain inhibitor peptide	iGluR	Neurological Disease
PDZ1 Domain inhibitor peptide, a cyclic peptide, incorporates a β-Ala lactam side chain linker and targets the PDZ1 domains of the postsynaptic density protein 95 (PSD-95). PDZ1 Domain inhibitor peptide disrupts the GluR6/PSD-95 interaction and is very efficient in competing against the C terminus of GluR6 for the PDZ1 domain .

HY-P3727

Lys-Pro-Pro-Thr-Pro-Pro-Pro-Glu-Pro-Glu-Thr	Peptides	Inflammation/Immunology
Lys-Pro-Pro-Thr-Pro-Pro-Pro-Glu-Pro-Glu-Thr is a undecapeptide, corresponding to the carboxy terminus of simian virus 40 large T antigen. Lys-Pro-Pro-Thr-Pro-Pro-Pro-Glu-Pro-Glu-Thr can be targeted by antibodies secreted from three mouse hybridomas, designated KT1, KT3, and KT4, produced antibodies that immunoprecipitated large T antigen .

HY-P1136

Gap19 5 Publications Verification	Gap Junction Protein	Cardiovascular Disease
Gap19, a peptide derived from nine amino acids of the Cx43 cytoplasmic loop (CL), is a potent and selective connexin 43 (Cx43) hemichannel blocker. Gap19 inhibits hemichannels caused by preventing intramolecular interactions of the C-terminus (CT) with the CL. Gap19 is not blocking GJ channels or Cx40/pannexin-1 hemichannels. Gap19 has protective effects against myocardial .

HY-P1195A

PDZ1 Domain inhibitor peptide TFA	iGluR	Neurological Disease
PDZ1 Domain inhibitor peptide TFA, a cyclic peptide, incorporates a β-Ala lactam side chain linker and targets the PDZ1 domains of the postsynaptic density protein 95 (PSD-95). PDZ1 Domain inhibitor peptide TFA disrupts the GluR6/PSD-95 interaction and is very efficient in competing against the C terminus of GluR6 for the PDZ1 domain .

HY-17573R

Carbetocin (Standard)	Reference Standards Oxytocin Receptor	Neurological Disease Endocrinology
Carbetocin (Standard) is the analytical standard of Carbetocin. This product is intended for research and analytical applications. Carbetocin, an oxytocin (OT) analogue, is an oxytocin receptor agonist with a K_i of 7.1 nM. Carbetocin has high affinity to chimeric N-terminus (E1) of the oxytocin receptor (K_i=1.17 μM). Carbetocin has the potential for postpartum hemorrhage research. Carbetocin can crosse the blood-brain barrier and produces antidepressant-like activity via activation of oxytocin receptors in the CNS .

HY-P1058

Pep2m	iGluR	Neurological Disease
Pep2m is a peptide receptor inhibitor. Pep2m inhibits the interaction between the C-terminus of the AMPA-type glutamate receptor (GluA2) subunit and N-ethylmaleimide-sensitive fusion protein (NSF). Pep2m prevents synaptic long-term depression (LTD). Pep2m can reduce postsynaptic currents in neurons, AMPA-mediated currents in cultured hippocampal neurons, and AMPA receptor surface expression ^{[1] [2] [3] [4] [5]}.

Cat. No.	Product Name	Target	Research Area

HY-P99963

Sudubrilimab HS636	PD-1/PD-L1	Cancer
Sudubrilimab (HS636) is an Ig G1-kappa monoclonal antibody against PDL1. Sudubrilimab is fused at the C terminus of the heavy chain to a TGF-β1 receptor Ⅱ ectodomain (TGFBR2-ECD), and which can sequester the PD-1/PD-L1 pathway and TGF-β bioactivity in the immunosuppressive tumor microenvironment .

HY-P99185

Bapineuzumab	Amyloid-β	Neurological Disease
Bapineuzumab is an anti-β-amyloid protein (APP) monoclonal antibody. Bapineuzumab is a humanized IgG1 that recognizes the N terminus of Aβ cleared plaques from the brains. Bapineuzumab can be used for the research of Alzheimer’s disease (AD) .

HY-P99163

Tilavonemab ABBV-8E12; C2N-8E12	Tau Protein	Neurological Disease
Tilavonemab (ABBV-8E12) is a humanized anti-tau monoclonal antibody that binds to amino acids 25-30 near the N-terminus of the tau protein. Tilavonemab can block the ability of human and mouse neurons to uptake tau aggregates. Tilavonemab can be used for research on Alzheimer’s disease and other tauopathies .

HY-P991676

Eflumenibep alfa	Kallikrein	Inflammation/Immunology
Eflumenibep alfa is a Kallikrein 5 inhibitor with anti-inflammatory activity. Eflumenibep alfa is a fusion protein that combines human SPINK2 with the human IgG1 Fc fragment at the C-terminus .

HY-P991680

Elipunercept	TNF Receptor	Inflammation/Immunology
Elipunercept is a fusion protein that combines human TNFRSF1B extracellular domain fragment (1-235) fused at the C-terminus to a human IgG1 Fc fragment. Elipunercept is an immunomodulator .

HY-P991678

Efpixileukin alfa	Interleukin Related	Inflammation/Immunology
Efpixileukin alfa is a fusion protein that combines human IL-2 variant fused at the C-terminus to human immunoglobulin G1 (IgG1) Fc fragment. Efpixileukin alfa is an immunomodulator .

HY-P3385

Rilunermin alfa SCB-313	Drug Derivative Apoptosis	Cancer
Rilunermin alfa (SCB-313) is a recombinant fusion protein composed of the human C-propeptide of alpha1(I) collagen (Trimer-Tag) to the C-terminus of the mature human tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL; Apo2L). Rilunermin alfa has potential pro-apoptotic and antineoplastic activities .

HY-P991073

MEDI-1814	Amyloid-β	Neurological Disease
MEDI-1814 is a fully human IgG1 antibody that targets the C terminus of Aβ42. MEDI-1814 binds to and sweeps away the circulated Aβ peptides, hence, restricting them from aggregating into toxic oligomers. MEDI-1814 can be used for the study of Alzheimer's diseases. The isotype control for MEDI-1814 can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P990088

Sotiburafusp alfa	VEGFR PD-1/PD-L1	Cardiovascular Disease
Sotiburafusp alfa is a bispecific fusion protein, which is a humanized VEGFR-1 extracellular domain fragment (129-228, 1-100 in the current sequence) fused via the peptide linker ¹⁰¹GGSGGSGGSGGSGGS ¹¹⁵ to the N-terminus of the heavy chain (116-564) of a humanized IgG1-kappa anti-human PD-L1 heavy chain variant L352>A, L353>A. Sotiburafusp alfa is also an angiogenesis inhibitor .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-W015450

D-Ala-D-Ala	Structural Classification Natural Products Human Gut Microbiota Metabolites Classification of Application Fields Source classification Other Diseases Endogenous metabolite Disease Research Fields	Endogenous Metabolite
D-Ala-D-Ala is a bacterial endogenous metabolite. D-Ala-D-Ala constitutes the terminus of the peptide part of the peptidoglycan monomer unit and is involved in the transpeptidation reaction as the substrate. D-Ala-D-Ala is catalyzed by D-Alanine-D-Alanine ligase .

HY-W015450R

D-Ala-D-Ala (Standard)	Structural Classification Natural Products Human Gut Microbiota Metabolites Source classification Endogenous metabolite	Reference Standards Endogenous Metabolite
D-Ala-D-Ala (Standard) is the analytical standard of D-Ala-D-Ala. This product is intended for research and analytical applications. D-Ala-D-Ala is a bacterial endogenous metabolite. D-Ala-D-Ala constitutes the terminus of the peptide part of the peptidoglycan monomer unit and is involved in the transpeptidation reaction as the substrate. D-Ala-D-Ala is catalyzed by D-Alanine-D-Alanine ligase .

HY-N15079

Arphamenine B	Structural Classification Microorganisms Antibiotics Source classification Other Antibiotics	Bacterial
Arphamenine B is a Zn ²⁺-dependent exopeptidase that selectively removes arginine and/or lysine residues from the NH2-terminus of several peptide substrates. Arphamenine B is an inhibitor of aminopeptidase B that can be isolated from bacteria. Arphamenine B enhances the immune response and is used to characterize novel proteases .

HY-N15973

DSPE PEG2k-OH ammonium	Structural Classification Lipid	Biochemical Assay Reagents
DSPE PEG2k-OH ammonium is a hydroxyl-terminated PEGylated phospholipid. The hydrophobic tail allows for the encapsulation and aggregation of other hydrophobic drugs, and the hydroxyl terminus is suitable for further reactions. DSPE PEG2k-OH ammonium can be used to prepare liposomes or lipid nanoparticles .

Cat. No.	Compare	Product Name	Species	Source

HY-P71340

	STUB1 Protein, Human 2 Publications Verification E3 Ubiquitin-Protein Ligase CHIP; Antigen NY-CO-7; CLL-Associated Antigen KW-8; Carboxy terminus of Hsp70-Interacting Protein; STIP1 Homology and U Box-Containing Protein 1; STUB1; CHIP	Human	E. coli
	STUB1 protein is an E3 ubiquitin protein ligase that cooperates with ATXN3 to regulate ubiquitin chain length on substrates and prevent chain extension. It ubiquitinates NOS1 through Hsp70/Hsp40 and regulates chaperone complexes (Hsp70, Hsc70, Hsp90). STUB1 Protein, Human is the recombinant human-derived STUB1 protein, expressed by E. coli , with tag free.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-176277S

Fibrinopeptide B, human-(Val-13C5,15N, Arg-13C6,15N4) TFA
Fibrinopeptide B, human-(Val- ¹³C₅, ¹⁵N, Arg- ¹³C₆, ¹⁵₄) TFA is the ¹³C- and ¹⁵N-labeled Fibrinopeptide B, human (HY-P1493). Fibrinopeptide B, human is a 14-aa peptide, released from the amino-terminus of β-chains of fibrinogen by thrombin .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P86907

	HUWE1 Antibody (YA6600) ARF binding protein 1 antibody; ARF BP1 antibody; ARF-binding protein 1 antibody; ARF-BP1 antibody; ARFBP1 antibody; BJ-HCC-24 tumor antigen antibody; E3 ubiquitin protein ligase HUWE1 antibody; E3 ubiquitin-protein ligase HUWE1 antibody; HECT antibody; HECT domain protein LASU1 antibody; ARF binding protein 1 antibody; ARF BP1 antibody; ARF-binding protein 1 antibody; ARF-BP1 antibody; ARFBP1 antibody; BJ-HCC-24 tumor antigen antibody; E3 ubiquitin protein ligase HUWE1 antibody; E3 ubiquitin-protein ligase HUWE1 antibody; HECT antibody; HECT domain protein LASU1 antibody; HECT UBA and WWE domain containing protein 1 antibody; HectH9 antibody; Homologous to E6AP carboxyl terminus homologous protein 9 antibody; Huwe1 antibody; HUWE1_HUMAN antibody; Ib772 antibody; Large structure of UREB1 antibody; LASU1 antibody; Mcl 1 ubiquitin ligase E3 antibody; Mcl-1 ubiquitin ligase E3 antibody; Mule antibody; UBA and WWE domain-containing protein 1 antibody; Upstream regulatory element-binding protein 1 antibody; URE-B1 antibody; URE-binding protein 1 antibody; UREB1 antibody;	WB, IHC-P, ICC/IF, FC	Human, Mouse, Rat
	HUWE1 Antibody (YA6600) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to HUWE1.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-140741

DSPE-PEG-OH, MW 2000 1 Publications Verification		Pegylated Lipids
DSPE-PEG-OH, MW 2000 is a hydroxyl-terminated PEGylated phospholipid. The hydrophobic tail allows for the encapsulation and aggregation of other hydrophobic drugs, and the hydroxyl terminus is suitable for further reactions. DSPE-PEG-OH, MW 2000 can be used to prepare liposomes or lipid nanoparticles .

HY-144013H

18:0 mPEG5000 PE ammonium DSPE-mPEG5000 ammonium; 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-5000] ammonium		Pegylated Lipids
18:0 mPEG5000 PE (ammonium) is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymeric nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-171573

3′-Azido-2′,3′-dideoxy-GTP AZddGTP		Nucleotide Analogs Guanine Nucleotide
3′-Azido-2′,3′-dideoxy-GTP (AZddGTP) is a selective telomerase inhibitor with a K_i value of 1.5 μM. 3′-Azido-2′,3′-dideoxy-GTP can be incorporated into the 3′-terminus of DNA by telomerase. 3′-Azido-2′,3′-dideoxy-GTP inhibits telomerase activity in HeLa cells in vitro .

HY-157712

08:0 PI(4,5)P2 ammonium		Phospholipids
08:0 PI(4,5)P2 ammonium is suitable for identifying its binding site at the transient receptor potential vanilloid 4 (TRPV 4 N) terminus .

HY-144012B

DPPE-PEG550 16:0 PEG550 PE; 1,2-Dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-550] ammonium		Pegylated Lipids
DPPE-PEG550 is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-144013B

18:0 mPEG550 PE ammonium DSPE-mPEG550 ammonium; 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-550] ammonium		Pegylated Lipids
18:0 mPEG550 PE (ammonium) is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymeric nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-144012C

DPPE-PEG750 16:0 PEG750 PE; 1,2-Dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-750] ammonium		Pegylated Lipids
DPPE-PEG750 is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-144012E

DPPE-PEG3000 16:0 PEG3000 PE; 1,2-Dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-3000] ammonium		Pegylated Lipids
DPPE-PEG3000 is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-144013A

18:0 mPEG350 PE ammonium DSPE-mPEG350 ammonium; 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-350] ammonium		Pegylated Lipids
18:0 mPEG350 PE (ammonium) is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-144013D

18:0 mPEG1000 PE ammonium DSPE-mPEG1000 ammonium; 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-1000] ammonium		Pegylated Lipids
18:0 mPEG1000 PE (ammonium) is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymeric nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-144012D

DPPE-PEG1000 16:0 PEG1000 PE; 1,2-Dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-1000] ammonium		Pegylated Lipids
DPPE-PEG1000 is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-144012H

DPPE-PEG5000 16:0 PEG5000 PE; 1,2-Dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-5000] ammonium		Pegylated Lipids
DPPE-PEG5000 is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-144013E

18:0 mPEG3000 PE ammonium DSPE-mPEG3000 ammonium; 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-3000] ammonium		Pegylated Lipids
18:0 mPEG3000 PE (ammonium) is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymeric nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-144013C

18:0 mPEG750 PE ammonium DSPE-mPEG750 ammonium; 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-750] ammonium		Pegylated Lipids
18:0 mPEG750 PE (ammonium) is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymeric nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-155926

DMPE-PEG750 ammonium 14:0 PEG750 PE ammonium; 1,2-Dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-750] ammonium		Pegylated Lipids
DMPE-PEG750 ammonium (14:0 PEG750 PE ammonium) is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymeric nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-155931

18:1 PEG550 PE ammonium DOPE-PEG550 ammonium; 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-550] ammonium		Pegylated Lipids
18:1 PEG550 PE ammonium (DOPE-PEG550 ammonium) is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-155924

DMPE-PEG350 ammonium 14:0 PEG350 PE ammonium; 1,2-Dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-350] ammonium		Pegylated Lipids
DMPE-PEG350 ammonium (14:0 PEG350 PE ammonium) is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-155927

DMPE-PEG1000 ammonium 14:0 PEG1000 PE ammonium; 1,2-Dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-1000] ammonium		Pegylated Lipids
DMPE-PEG1000 ammonium (14:0 PEG1000 PE ammonium) is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-155934

18:1 PEG5000 PE ammonium DOPE-PEG5000 ammonium; 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-5000] ammonium		Pegylated Lipids
18:1 PEG5000 PE ammonium (DOPE-PEG5000 ammonium) is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-155933

18:1 PEG3000 PE ammonium DOPE-PEG3000 ammonium; 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-3000] ammonium		Pegylated Lipids
18:1 PEG3000 PE ammonium (DOPE-PEG3000 ammonium) is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-155932

18:1 PEG1000 PE ammonium DOPE-PEG1000 ammonium; 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-1000] ammonium		Pegylated Lipids
18:1 PEG1000 PE ammonium (DOPE-PEG1000 ammonium) is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-155925

DMPE-PEG550 ammonium 14:0 PEG550 PE ammonium; 1,2-Dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-550] ammonium		Pegylated Lipids
DMPE-PEG550 ammonium (14:0 PEG550 PE ammonium) is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymeric nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-155930

18:1 PEG350 PE ammonium DOPE-PEG350 ammonium; 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-350] ammonium		Pegylated Lipids
18:1 PEG350 PE ammonium (DOPE-PEG350 ammonium) is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-155929

DMPE-PEG5000 ammonium 14:0 PEG5000 PE ammonium; 1,2-Dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-5000] ammonium		Pegylated Lipids
DMPE-PEG5000 ammonium (14:0 PEG5000 PE ammonium) is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

HY-155928

DMPE-PEG3000 ammonium 14:0 PEG3000 PE ammonium; 1,2-Dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-3000] ammonium		Pegylated Lipids
DMPE-PEG3000 ammonium (14:0 PEG3000 PE ammonium) is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles. Through biotin modification and carboxyl terminus, lipid nanoparticles (LNPs) further coupling with other biomolecules can be achieved. Functionalized nanoparticles can be used for targeted labeling of specific cellular proteins. With streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles are able to bind to biotinylated antibodies on cell surface receptors, yielding the utility of fluorescence-based imaging and sensing.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

terminus

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Natural
Products